Broncus Announced Long-Term Follow-Up Data on InterVapor, Showing Stable Long-Term Efficacy in Patients

The follow-up data show that no serious adverse events associated with InterVapor® were reported after BTVA treatment. The 36-month efficacy data suggest that patients' pulmonary function, exercise tolerance, and symptom score showed better benefits compared with those treated with standard medications. And the development trend of lung diseases in patients showed decline. These facts well verified long-term safety and stable efficacy of BTVA. The follow-up data show that no serious adverse...

The follow-up data show that no serious adverse events associated with InterVapor^® were reported after BTVA treatment. The 36-month efficacy data suggest that patients' pulmonary function, exercise tolerance, and symptom score showed better benefits compared with those treated with standard medications. And the development trend of lung diseases in patients showed decline. These facts well verified long-term safety and stable efficacy of BTVA.

Using InterVapor^®, BTVA reduces the volume of emphysematous segments by inducing a local inflammatory response to water vapor. BTVA, an ELVR technique, is included in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) treatment guidelines for five consecutive years from 2019 to 2023, which is recommended for patients with severe and acutely severe COPD.

Currently, InterVapor^® has been approved for marketing in China, the European Union and major European countries, including France, Germany, the United Kingdom, and Italy. With increasing clinical data and experiences, it is becoming a therapy for more COPD patients worldwide.

The release of the long-term follow-up data well proves the long-term real-world safety and efficacy of BTVA. Looking ahead, Broncus will spare no effort to promote InterVapor^® in the world, striving to bring more patients long-acting and safe COPD therapies.

Photo - https://mma.prnewswire.com/media/2213202/2.jpg

View original content:https://www.prnewswire.co.uk/news-releases/broncus-announced-long-term-follow-up-data-on-intervapor-showing-stable-long-term-efficacy-in-patients-301930284.html